GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT00154414

CompletedPhase 2

Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 Diabetes

Effect of Liraglutide on Glycaemic Control in Japanese Subjects With Type 2 Diabetes.

Lead sponsor

Novo Nordisk A/S

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

226

actual

Study population

Type 2 diabetes

Key I/E criteria

•BMI ≤30•HbA1c ≤10%

Primary endpoint

•HbA1c, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT00154414

Org study IDNN2211-1334

Secondary IDJapicCTI-050131Japic

Timeline

Milestones

Study first posted2005-09-12estimated

Last update posted2017-01-25estimated

Study start2005-01 (month precision)

Primary completion2006-05actual (month precision)

Study completion2006-05actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age20 Years

Maximum age74 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Subjects diagnosed with type 2 diabetes and treated with diet therapy with or without single oral drug therapy

•7.0 % =< HbA1c < 10.0 %

•Body Mass Index (BMI) < 30.0 kg/m^2

Exclusion criteria

•Subjects treated with thiazolidinediones or insulin

•Subjects with any serious medical conditions

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes

Weight & body composition

Safety / tolerability / PK

Weight & body composition

1 endpoint

Secondary/protocol endpoint

Body weight after 14 weeks.

descriptive, improvement

Glycemic / diabetes

2 endpoints

Primary/protocol endpoint

HbA1c

Time frame:after 14 weeks treatment

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Glycaemic control parameters (fasting plasma glucose, post prandial plasma glucose) after 14-week treatment

change from baseline, improvement

Safety / tolerability / PK

1 endpoint

Secondary/protocol endpoint

Safety and tolerability

Treatment-emergent AEs (any)

descriptive

Publications (2)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
Diabetes care2015 Jun (month)PMID25504028doi:10.2337/dc13-1210via CT.gov reference
Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes.
Diabetes research and clinical practice2008 Aug (month)PMID18495285doi:10.1016/j.diabres.2008.03.018via CT.gov reference

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.